Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 417-422

  Hilkens, P H E ^a   Pronk, L C ^a   Verweij, J ^a   Vecht, C J ^a   Van Putten, W L J ^a   Van Den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Neuropathy; Neurotoxicity; Peripheral nerves

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; VIBRATION SENSE;

EID: 0031027660     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.68     Document Type: Article

References (34)

1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR and Verweij J (1994) Docetaxel (taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group. Eur J Cancer 30A: 1061-1064
2. Apfel SC, Arezzo JC, Lipson LA and Kessler JA (1992) Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol, 31: 76-80
3. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Lebail N, Kaye SB and Kerr DJ (1993) Phase I and Pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527
4. Bruntsch U, Heinrich B, Kaye SB, Mulder DE, PHM, Oosterom Van A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M and Verweij J (1994) Docetaxel (taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group. Eur J Cancer 30A: 1064-1067
5. Cascinu S, Cordella L, Del Ferro E, Fronzoni M and Catalano G (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastic cancer: a randomized double blind placebo-controlled trial. J Clin Oncol 13: 26-32
6. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC and Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304-311
7. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski J, Azli N, Buyssas M, Lentz MA and Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the europcan organization for research and treatment of cancer. J Clin Oncol 13: 314-322
8. DI RE F, Bohm S, Oriani S, Spatti GB, Pirovano C, Tedeschi M and Zunino F (1993) High-dose cisplatin and cyclophosphamide with gluathione in the treatment of advanced ovarian cancer. Ann Ontol 4: 55-61
9. Elderson A, Gerrilsen Van Der Hoop R, Haanstra W, Neijt JP, Gispen WH and Jennekens FGI (1989) Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 93: 167-174
10. Extra JM, Rousseau F, Bruno R, Clavel F, Lebail N and Marty M (1993) Phase I and Pharmacokinetic study of taxotere (RP 56976, NSC 628503) given as a short infusion. Cancer Res 53: 1037-1042
11. Fossella F, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chase M, Shin DM, Glisson B, Benner B, Huber M, Perez-Soler R, Hong WK and Raber M (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238-1244
12. Francis PA, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M and Hakes T (1994a). Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301-2308
13. Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woollley KJ and Heelan RT (1994b) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237
14. Gandara DR, Perez EA, Wiebe V and Degregorio MW (1991) Cisplatin chemoprotection and rescue: pharmacologie modulation of toxicity. Semin Oncol 18: 49-55
15. Gerritsen Van Der Hoop R, Van Der Burg Mel, Ten Bokkel Huinink WW, Van Houwelingen JC and Neijt JP (1990a). Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66: 1697-1702
16. Gerritsen Van Der Hoop R, Vecht CJ, Van Der Burg Mel, Elderson A, Boogerd W, Heimans JJ, Vries FP, Van Houwelingen JC, Jennekens FGI, Gispen WH and Neijt JP (1990b). Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 322: 89-94.
17. Gerven Van, JMA, Moll JWB, Bent Van Den, MJ, Bontebal M, Burg Van Der, MEL, Verweij J and Vecht Chj (1994) Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A: 1074-1077
18. Goldberg JM and Lindblom U (1979) Standardised method of determining vibratory perception tresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 42: 793-803
19. Hilkens PHE, Planting Ast, Van Der Burg Mel, Moll Jwb, Van Putten Wlj, Vecht Chj and Van Den Bent MJ (1994) Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1: 45-50
20. Hilkens Phe, Verweij J, Stoter G, Vecht Chj, Van Putten WLJ and Van Den Bent MJ (1996) Peripheral neurotoxiciyv induced by docetaxel. Neurology 46: 104-108
21. Hovestadt A, Van Der Burg Mel, Verbiest HBC, Van Putten Wlj and Vecht CJ (1992) The course of neuropathy alter cassation of cisplation treatment, combined with org 2766 or placebo. J Neurol 239: 143-146
22. Lipton RB, Apfel SC, Dutcher JP, Rosenburg R, Kuplan J, Berger A, Einzig AI, Wiernik P and Schaumburg HH (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39: 368-373.
23. Mollman JE, Glover DJ, Hogan WM and Furman RH (1988) Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195
24. New PZ, Jackson CH, Rinaldi D, Burris H and Barohn RJ (1996) Neurotoxicity of docetaxel (taxotere). Neurology 46: 108-111
25. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR and Raher MN (1993) The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351-386
26. Pronk LC, Schellens JHM, Planting AST, Van Den Bent MJ, Van Der Burg Mel, De Boer-Dennert M, Blanc C, Harteveld M, Bruno R, Stoter G and Verweij J (1996) A phase 1 and pharmacologie study of docetaxel and cisplatin in patients with advanced solid tumors. Clin Oncol (in press)
27. Roelofs RI, Hrushesky W, Rogin J and Rosenberg L (1984) Peripheral sensory neuropathy and cisplalin chemotherapy. Neurology 34: 934-938
28. Rowinsky HK, Gilben MR, Meguire WP, Noe DA, Grochow LB. Forastiere AA, Ettinger DS, Lubejko BG, Sartorius SH, Cornblath Dr, Hendricks CB and Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacological study. J Clin Oncol 9: 1692-1703
29. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SH, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR and Donehower RC (1993) Phase I and pharmacological study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020
30. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H and Kaye SB (1994) Activity of docetaxel (taxotere) in small cell lung cancer. Fur J Cancer 30A: 1058-1060
31. Thompson SWE, Davis LE, Kornfeld M, Hilgers RD and Standefer JC (1984) Cisplatin neuropathy: clinical, eletrophysiologic, morphologic, and toxicologic studies. Cancer 54: 1269-1275
32. Vecht CJ, Movestadt A, Verbiest HBC, Van Putten Wlj, Neijt JP and Van Der Burg Mel (1991) Org 2766 in the prevention of cisplation neuropathy. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy SB Howell (ed.), pp. 501-508. Plenum press: New York
33. Wadler S, Beitler JJ, Ruhin JS, Haynes H, Megill F, Rozenblit A, Goldberg G, Cohen C, Speyer J and Runowicz C (1993) Pilot trial of cisplatin, radiation, and WR 2721 in carcinoma of the uterine cervix: a New York gynecologic oncology group study. J Clin Oncol 11: 1511-1516
34. Windebank AJ, Smith AG and Russell JW (1994) The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 44: 488-494